

Subject Index

- AIDS**, Dideoxynucleoside 2'-substituted, 2'-AZT, Activity anti-HIV, Solid state conformation, 357
- 2'-AZT**, Dideoxynucleoside 2'-substituted, Activity anti-HIV, AIDS, Solid state conformation, 357
- AZT**, HIV, Phosphoramidate derivative, 345
- Acquired immunodeficiency syndrome**, SIV, Antiretroviral agent, 87
- Activity anti-HIV**, Dideoxynucleoside 2'-substituted, 2'-AZT, AIDS, Solid state conformation, 357
- Acyclic nucleotide**, Human papillomavirus type 11, Cottontail rabbit papillomavirus, Athymic mouse, Domestic rabbit, PMEG, 51
- Acyclovir**, Brovavir, Encephalitis, Model infection, 99
- Acyclovir**, Herpes simplex virus, Thymidine kinase inhibitor, Experimental treatment, 207
- Amphotericin B**, HIV, Syncytium formation, 149
- Animal model**, Ganciclovir, HOE 602, Herpesvirus, Cytomegalovirus, 61
- Anti-HIV activity**, Hyssop Officinalis, Caffeic acid, 323
- Anti-HIV drug**, Dideoxynucleoside analog, Structure-activity correlation, Rational drug design, 125
- Anti-RNA virus activity**, Guanine 7-N-oxide, 173
- Antiretroviral agent**, SIV, Acquired immunodeficiency syndrome, 87
- Antiviral activity**, 3-Imino-5-phenyl-3H-1,2-dithiole poliovirus type 1, 267
- Antiviral therapy**, Herpes simplex virus, Topical drug formulation, Clinical trial, 305
- Arenavirus**, Nucleoside analogue, Sulfated polysaccharide, 287
- Athymic mouse**, Human papillomavirus type 11, Cottontail rabbit papillomavirus, Domestic rabbit, Acyclic nucleotide, PMEG, 51
- Bradykinin antagonist (NPC 567)**, Rhinovirus, Human volunteer, 339
- Brovavir**, Acyclovir, Encephalitis, Model infection, 99
- Caffeic acid**, Hyssop Officinalis, Anti-HIV activity, 323
- Carbocyclic 3-deazaadenosine**, Respiratory syncytial virus, Parainfluenza virus type 3, Cotton rat, 215
- Chemotherapy**, Drug interaction, Three-dimensional, Synergy, 181
- Clinical trial**, Herpes simplex virus, Topical drug formulation, Antiviral therapy, 305
- Combined antiviral effect**, Guinea pig cytomegalovirus, Nucleoside, Dose-effect analysis, 249
- Cotton rat**, Respiratory syncytial virus, Parainfluenza virus type 3, Carbocyclic 3-deazaadenosine, 215
- Cotton rat**, LY253963, Respiratory syncytial virus, Parainfluenza virus, 237
- Cottontail rabbit papillomavirus**, Human papillomavirus type 11, Athymic mouse, Domestic rabbit, Acyclic nucleotide, PMEG, 51
- Cytomegalovirus**, Ganciclovir, HOE 602, Herpesvirus, Animal model, 61
- Cytotoxicity**, Influenza virus inhibition, LY253963, Ribavirin, Rimantadine, 25
- Dextran sulfate**, Influenza virus, Liposome, Fluorescence spectroscopy, Membrane fusion, 39
- Dideoxynucleoside analog**, Anti-HIV drug, Structure-activity correlation, Rational drug design, 125
- Dideoxynucleoside 2'-substituted**, 2'-AZT, Activity anti-HIV, AIDS, Solid state conformation, 357
- Domestic rabbit**, Human papillomavirus type 11, Cottontail rabbit papillomavirus, Athymic mouse, Acyclic nucleotide, PMEG, 51
- Dose-effect analysis**, Combined antiviral effect, Guinea pig cytomegalovirus, Nucleoside, 249
- Drug interaction**, Three-dimensional, Chemotherapy, Synergy, 181
- Drug-resistant mutant**, Herpes simplex virus, PMEA, 9-(2-Phosphonylmethoxythyl)adenine, 117
- Encephalitis**, Brovavir, Acyclovir, Model infection, 99
- Estrous cycle**, Herpes simplex virus, Vaginal inoculation, 227
- Experimental treatment**, Herpes simplex virus, Thymidine kinase inhibitor, Acyclovir, 207
- Fluorescence spectroscopy**, Dextran sulfate, Influenza virus, Liposome, Membrane fusion, 39
- Fusion**, Tromantadine, HSV-1, Syncytium formation, 75

- Ganciclovir**, HOE 602, Herpesvirus, Cytomegalovirus, Animal model, 61
- Guanine 7-N-oxide**, Anti-RNA virus activity, 173
- Guinea pig cytomegalovirus**, Combined antiviral effect, Nucleoside, Dose-effect analysis, 249
- HIV**, Amphotericin B, Syncytium formation, 149
- HIV**, Oriental plant extract, Inhibition, Reverse transcriptase, p24, 279
- HIV**, Phosphoramidate derivative, AZT, 345
- HOE 602**, Ganciclovir, Herpesvirus, Cytomegalovirus, Animal model, 61
- HSV-1**, Tromantadine, Syncytium formation, Fusion, 75
- Herpes simplex virus**, PMEAs, 9-(2-Phosphonylmethoxythyl)adenine, Drug-resistant mutant, 117
- Herpes simplex virus**, Thymidine kinase inhibitor, Acyclovir, Experimental treatment, 207
- Herpes simplex virus**, Estrous cycle, Vaginal inoculation, 227
- Herpes simplex virus**, Topical drug formulation, Clinical trial, Antiviral therapy, 305
- Herpesvirus**, Ganciclovir, HOE 602, Cytomegalovirus, Animal model, 61
- Human immunodeficiency virus**, *O,O'*-bis(3'-azido-3'-deoxythymidin-5'-yl)methylphosphonate, *O,O'*-bis(2',3'-dideoxycytidin-5'-yl)methylphosphonate, 11
- Human papillomavirus type 11**, Cottontail rabbit papillomavirus, Athymic mouse, Domestic rabbit, Acyclic nucleotide, PMEG, 51
- Human volunteer**, Rhinovirus, Bradykinin antagonist (NPC 567), 339
- Hyssop Officinalis**, Caffeic acid, Anti-HIV activity, 323
- 3-Imino-5-phenyl-3H-1,2-dithiole poliovirus type 1**, Antiviral activity, 267
- Indometacin**, Prostaglandin E2, Interferon, Multiplication of HSV-1, 161
- Influenza virus inhibition**, LY253963, Ribavirin, Rimantadine, Cytotoxicity, 25
- Influenza virus**, Dextran sulfate, Liposome, Fluorescence spectroscopy, Membrane fusion, 39
- Influenza virus**, Serum IgG, 109
- Inhibition**, HIV, Oriental plant extract, Reverse transcriptase, p24, 279
- Interferon α -2a**, RSV infection, Prophylaxis, Therapy, 3
- Interferon**, Indometacin, Prostaglandin E2, Multiplication of HSV-1, 161
- LY253963**, Influenza virus inhibition, Ribavirin, Rimantadine, Cytotoxicity, 25
- LY253963**, Respiratory syncytial virus, Parainfluenza virus, Cotton rat, 237
- Liposome**, Dextran sulfate, Influenza virus, Fluorescence spectroscopy, Membrane fusion, 39
- Membrane fusion**, Dextran sulfate, Influenza virus, Liposome, Fluorescence spectroscopy, 39
- Model infection**, Brevovir, Acyclovir, Encephalitis, 99
- Multiplication of HSV-1**, Indometacin, Prostaglandin E2, Interferon, 161
- Nucleoside**, Combined antiviral effect, Guinea pig cytomegalovirus, Dose-effect analysis, 249
- Nucleoside analogue**, Arenavirus, Sulfated polysaccharide, 287
- O,O'-bis(3'-azido-3'-deoxythymidin-5'-yl)methylphosphonate**, Human immunodeficiency virus, 11
- O,O'-bis(2',3'-dideoxycytidin-5'-yl)methylphosphonate**, Human immunodeficiency virus, 11
- Oriental plant extract**, HIV, Inhibition, Reverse transcriptase, p24, 279
- p24**, HIV, Oriental plant extract, Inhibition, Reverse transcriptase, 279
- PMEA**, Herpes simplex virus, 9-(2-Phosphonylmethoxythyl)adenine, Drug-resistant mutant, 117
- PMEG**, Human papillomavirus type 11, Cottontail rabbit papillomavirus, Athymic mouse, Domestic rabbit, Acyclic nucleotide, 51
- Parainfluenza virus type 3**, Respiratory syncytial virus, Carbocyclic 3-deazaadenosine, Cotton rat, 215
- Parainfluenza virus**, LY253963, Respiratory syncytial virus, Cotton rat, 237
- 9-(2-Phosphonylmethoxythyl)adenine**, Herpes simplex virus, PMEAs, Drug-resistant mutant, 117
- Phosphoramidate derivative**, HIV, AZT, 345
- Prophylaxis**, Interferon α -2a, RSV infection, Therapy, 3
- Prostaglandin E2**, Indometacin, Interferon, Multiplication of HSV-1, 161
- RSV infection**, Interferon 2a, Prophylaxis, Therapy, 3

- Rational drug design**, Dideoxynucleoside analog, Anti-HIV drug, Structure-activity correlation, 125
- Respiratory syncytial virus**, Parainfluenza virus type 3, Carbocyclic 3-deazaadenosine, Cotton rat, 215
- Respiratory syncytial virus**, LY253963, Parainfluenza virus, Cotton rat, 237
- Reverse transcriptase**, HIV, Oriental plant extract, Inhibition, p24, 279
- Rhinovirus**, Bradykinin antagonist (NPC 567), Human volunteer, 339
- Ribavirin**, Influenza virus inhibition, LY253963, Rimantadine, Cytotoxicity, 25
- Rimantadine**, Influenza virus inhibition, LY253963, Ribavirin, Cytotoxicity, 25
- SIV**, Acquired immunodeficiency syndrome, Antiretroviral agent, 87
- Serum IgG**, Influenza virus, 109
- Solid state conformation**, Dideoxynucleoside 2'-substituted, 2'-AZT, Activity anti-HIV, AIDS, 357
- Structure-activity correlation**, Dideoxynucleoside analog, Anti-HIV drug, Rational drug design, 125
- Sulfated polysaccharide**, Arenavirus, Nucleoside analogue, 287
- Syncytium formation**, Tromantadine, HSV-1, Fusion, 75
- Syncytium formation**, HIV, Amphotericin B, 149
- Synergy, Drug interaction**, Three-dimensional, Chemotherapy, 181
- Therapy**, Interferon α -2a, RSV infection, Prophylaxis, 3
- Three-dimensional**, Drug interaction, Chemotherapy, Synergy, 181
- Thymidine kinase inhibitor**, Herpes simplex virus, Acyclovir, Experimental treatment, 207
- Topical drug formulation**, Herpes simplex virus, Clinical trial, Antiviral therapy, 305
- Tromantadine**, HSV-1, Syncytium formation, Fusion, 75
- Vaginal inoculation**, Herpes simplex virus, Estrous cycle, 227